RxDoctor Payments Data

Daniela Mihova, MD

Anatomic Pathology & Clinical Pathology · Frederick, MDNPI 1205090412

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AstraZeneca at 30.6% of the total. Reporting peaked in 2022 at $90 and has fallen 56.3% since, to $39 in 2025.

$281in general payments, 2019–2025

Across 12 payments — averaging $23.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$86
  • Roche Diagnostics Corporation$62
  • Foundation Medicine, Inc.$36
  • Lilly USA, LLC$30
  • Biocartis US, Inc$26
  • Merck$16
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$281100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$86
Roche Diagnostics Corporation3$62
Foundation Medicine, Inc.2$36
Lilly USA, LLC2$30
Biocartis US, Inc1$26
Merck1$16
Genentech USA, Inc.1$15
Werfen USA LLC1$9

How this compares

$281 in reported general payments places this provider in the 70th percentile of 186 anatomic pathology & clinical pathology providers in Maryland.

See all anatomic pathology & clinical pathology providers in Maryland

Medicare billing

Part B allowed, 2024
$208,906
Medicare patients
1,120
Services billed
5,930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology & clinical pathology in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →